Acamprosate for C9orf72 mutation
Amyotrophic lateral sclerosis (ALS) patients with a C9orf72 mutation may take part in a study of acamprosate to see if it is safe and could slow the disease. The drug has shown potential to protect nerve cells in lab studies, and the trial will monitor safety, symptoms, daily function, mood, and scans over 32 weeks with clinic and phone visits.
Research#C9orf72#Clinical Trial#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)